Related references
Note: Only part of the references are listed.Translational genomics of nasopharyngeal cancer
Chi Man Tsang et al.
SEMINARS IN CANCER BIOLOGY (2020)
Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma
Jin Zhao et al.
CANCER LETTERS (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis
Bi-Cheng Wang et al.
ORAL ONCOLOGY (2020)
Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.
Fenghua Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV plus NPC).
Lillian L. Siu et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
Yuxiang Ma et al.
ONCOLOGIST (2019)
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Yuan Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu et al.
JAMA ONCOLOGY (2019)
Management of locally recurrent nasopharyngeal carcinoma
Anne W. M. Leea et al.
CANCER TREATMENT REVIEWS (2019)
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti et al.
DRUG RESISTANCE UPDATES (2019)
Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
Anna Makowska et al.
TRANSLATIONAL ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis
Ya-Qin Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC)
Darren Wan-Teck Lim et al.
CANCER RESEARCH (2019)
Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma
Marc L. Ooft et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Salvage Treatment Using Carbon Ion Radiation in Patients With Locoregionally Recurrent Nasopharyngeal Carcinoma: Initial Results
Jiyi Hu et al.
CANCER (2018)
Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
Edwin P. Hui et al.
CLINICAL CANCER RESEARCH (2018)
Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma
Juan Lu et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2018)
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
Brigette B. Y. Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial
Anthony T. C. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study)
K. H. Au et al.
ORAL ONCOLOGY (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma
Eugenia L. L. Yeo et al.
CHINESE CLINICAL ONCOLOGY (2018)
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial
Su-Mei Cao et al.
EUROPEAN JOURNAL OF CANCER (2017)
Phase 2 Multicenter Trial Evaluating the Role of Induction TPF Followed by Weekly Docetaxel and Cetuximab in Combination With IMRT for Locally Recurrent Nasopharyngeal Carcinoma
W. T. Ng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Chiun Hsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis
Laureen Ribassin-Majed et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer
Oscar Siu Hong Chan et al.
ORAL ONCOLOGY (2017)
Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma
Marc L. Ooft et al.
ORAL ONCOLOGY (2017)
Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
Yvonne Y. Li et al.
NATURE COMMUNICATIONS (2017)
Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes
Qian Zhu et al.
ONCOIMMUNOLOGY (2017)
The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment
Tseng-Cheng Chen et al.
SCIENTIFIC REPORTS (2017)
Combining radiotherapy with immunotherapy: the past, the present and the future
Evert J. Van Limbergen et al.
BRITISH JOURNAL OF RADIOLOGY (2017)
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
Ying-Fei Li et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
Li Zhang et al.
LANCET (2016)
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
Ying Sun et al.
LANCET ONCOLOGY (2016)
Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
Anne W. M. Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
Pierre Blanchard et al.
LANCET ONCOLOGY (2015)
Local failure patterns for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy
Jia-xin Li et al.
RADIATION ONCOLOGY (2014)
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Wenfeng Fang et al.
ONCOTARGET (2014)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature
Chang-Chuan Pan et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2012)
Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation
E. P. Hui et al.
ANNALS OF ONCOLOGY (2011)
Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma
Edwin P. Hui et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer
Daniel Chua et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
